10 Most Undervalued NYSE Stocks to Invest In

8. Medtronic (NYSE:MDT)

Number of Hedge Fund Holders: 60

Medtronic (NYSE:MDT) is one of the most undervalued NYSE stocks to invest in. On June 12, Medtronic officially completed its acquisition of Scientia Vascular, a Salt Lake City-based medical device firm, in a transaction valued at $550 million. The deal includes potential post-acquisition earn-outs and milestone payments, and it marks a significant move for Medtronic to bolster its neurovascular portfolio by integrating Scientia’s specialized access technologies.

Scientia is recognized for its high-performance guidewires and catheters, which are specifically designed to navigate the complex and tortuous anatomy of the cerebral vasculature. By combining these products with Medtronic’s existing suite of neurovascular tools, the company aims to provide physicians with a more streamlined, integrated platform that simplifies procedures, reduces access challenges, and improves overall procedural efficiency in life-critical stroke treatments.

This acquisition aligns with Medtronic’s focus on high-growth opportunities and is expected to be minimally dilutive to its adjusted earnings per share in fiscal year 2027, with anticipated accretion thereafter. Leadership from both companies emphasized that the integration will leverage Medtronic’s global scale to expand the reach of these technologies, ultimately supporting the company’s long-term mission to improve patient outcomes and transform the future of neurovascular care.

Medtronic (NYSE:MDT) is a medical technology company that manufactures, distributes, and sells device-based medical services and therapies. It operates under four primary segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit.